China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a significant research service cooperation agreement with fellow firm Sino Biopharmaceutical Ltd (HKG: 1177). This partnership aims to empower Sino Biopharmaceutical in the development of a first-in-class monoclonal antibody (mAb), with the target currently undisclosed.
Comprehensive Research Services for Innovative mAb Development
According to the agreement, WuXi Biologics will leverage its integrated research services and leading antibody discovery technology platforms, such as single-cell technology platforms, to generate antibodies based on targets specified by Sino Biopharmaceutical. This collaboration will encompass lead antibody discovery, optimization, and feasibility evaluation, with the goal of screening the best candidate mAbs from the preclinical development stage.
Sino Biopharmaceutical Takes the Lead in mAb Development and Commercialization
Sino Biopharmaceutical will secure exclusive rights to the monoclonal antibody and will take the lead in subsequent Investigational New Drug (IND) filings, clinical trials, and product commercialization. This strategic move positions Sino Biopharmaceutical at the forefront of innovative drug development, bolstering its pipeline with a potentially groundbreaking therapy.
Financial Arrangements and Project Progress
WuXi Biologics is set to receive corresponding payments that are contingent upon the project’s development and commercialization progress. This financial structure aligns incentives and ensures that both parties are committed to the successful advancement of the first-in-class monoclonal antibody from the research phase to market availability.Fineline Info & Tech
